DOI: 10.1128/AAC.46.5.1561-1563.2002
Article Figures & Data
Figures
- FIG. 1.
Fold increases in MICs of wild-type MRSA and MRSE to moxifloxacin, levofloxacin, and trovafloxacin after exposure to moxifloxacin, levofloxacin, or trovafloxacin. (For example, after MRSA W87 was exposed to levofloxacin for 24 h in an aerobic environment, regrowth was associated with a fourfold increase in the MICs of moxifloxacin and levofloxacin and an eightfold increase in the MIC of trovafloxacin.) No S. epidermidis W126 isolates were recovered at 24 h from in vitro experiments with moxifloxacin.
- FIG. 2.
Activities of levofloxacin, moxifloxacin, and trovafloxacin against S. aureus W87 and S. epidermidis W126.
Tables
- TABLE 1.
MICs and MBCs for bacteria before antibiotic exposure
Bacteria Pre-antibiotic exposure MIC or MBC (mg/liter) Levofloxacin Trovafloxacin Moxifloxacin MSSA ATCC 29213 0.25 0.03 0.06 MRSA ATCC 33592 0.25 0.03 0.06 MRSA W87 8 2 2 MSSE ATCC 12228 0.25 0.06 0.12 MRSE ATCC 51625 0.25 0.03 0.06 MRSE W126 4 2 1
